United States biological products, excluding disgnostic substances industry landscape illustrating listed-company operations, infrastructure and market activity

Prism Finance USA · comparison snapshot

Biological Products, Excluding Disgnostic Substances Stocks in USA: Prism Readiness Cohort 9

Name: Biological Products, Excluding Disgnostic Substances Stocks in USA: Prism Readiness Cohort 9 comparison snapshot
Creator: Fliar BI Prism

A five-company biological products, excluding disgnostic substances cohort selected by Prism readiness, then compared across market path, filings, profitability, readiness, Prism attention and industry context.

Snapshot: 02 September 2026Not investment adviceRanked by Prism readiness

Readiness leaderCel-Sci · 40

Strongest available pathLineage Cell Therapeutics · -56.0%

Widest latest marginArsanis · -225.6%

Companies compared5 · U.S.-listed

01 · Readiness ranking

Five companies, one comparable score

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Readiness #1CVM · NYSE

Cel-Sci

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 1983Vienna, Virginia$29.0M market cap

View full Companies Radar profile

40Cautious

Snapshot price$1.65as of page date

Monthly-close return-99.5%five-year window

FY2014 revenue$0.00BCEL SCI CORP

Net margin-10364.7%FY2014

P/E snapshot-0.3xone ratio, not a verdict

Prism attention15.9%share across these five

Filing track recordRevenue, USD billions

+3.7%

FY2012–FY2014 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 1.8%

52-week position6% through range

$0.89$12.68

News mentions881

Community mentions45partial coverage

U.S.-scope patents71

Prism InsightsWhat sits behind the readiness signal
Observed risk 10/100higher means more observed risk

Earnings signal39/100
Management stability90/100
Market position5/100
Capital-event signal81/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 2 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

Recent available records contain 0 lawsuit, 4 regulatory and 0 layoff events across their stated windows.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #2FATE · Nasdaq

Fate Therapeutics

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2007San Diego, California$293.6M market cap

View full Companies Radar profile

39Cautious

Snapshot price$2.45as of page date

Monthly-close return-95.9%five-year window

FY2025 revenue$0.01BFATE THERAPEUTICS INC

Net margin-2051.1%FY2025

P/E snapshot-2.5xone ratio, not a verdict

Prism attention21.8%share across these five

Filing track recordRevenue, USD billions

-88.1%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -41.3%

52-week position66% through range

$0.93$3.23

News mentions1.2K

Community mentions85partial coverage

U.S.-scope patents611

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal33/100
Management stability90/100
Market position0/100
Capital-event signal59/100
Innovation pulse10/100

Management signal

No leadership-churn flag in the model; 1 key-person event recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 6 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #3OCGN · Nasdaq

Histogenics

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2013Aurora, Colorado$447.6M market cap

View full Companies Radar profile

38Cautious

Snapshot price$1.32as of page date

Monthly-close return-81.6%five-year window

FY2025 revenue$0.00BOcugen, Inc.

Net margin-1537.4%FY2025

P/E snapshot-4.9xone ratio, not a verdict

Prism attention33.5%share across these five

Filing track recordRevenue, USD billions

-26.9%

FY2023–FY2025 · 3 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR -14.5%

52-week position18% through range

$1.01$2.73

News mentions1.9K

Community mentions29partial coverage

U.S.-scope patents120

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal53/100
Management stability90/100
Market position3/100
Capital-event signal25/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 0 asset-acquisition events and 1 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #4XFOR · Nasdaq

Arsanis

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 2014Boston, Massachusetts$400.6M market cap

View full Companies Radar profile

37Cautious

Snapshot price$4.04as of page date

Monthly-close return-97.5%five-year window

FY2025 revenue$0.04BX4 Pharmaceuticals, Inc

Net margin-225.6%FY2025

P/E snapshot2.8xone ratio, not a verdict

Prism attention12.7%share across these five

Filing track recordRevenue, USD billions

+903.2%

FY2018–FY2025 · 4 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 115.7%

52-week position61% through range

$2.80$4.83

News mentions704

Community mentions3partial coverage

U.S.-scope patents2

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal50/100
Management stability90/100
Market position3/100
Capital-event signal29/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 1 M&A involvements, 0 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

Readiness #5LCTX · NYSE

Lineage Cell Therapeutics

A U.S.-listed issuer classified by the SEC in Biological Products, Excluding Disgnostic Substances

Founded 1990Carlsbad, California$280.7M market cap

View full Companies Radar profile

37Cautious

Snapshot price$1.11as of page date

Monthly-close return-56.0%five-year window

FY2025 revenue$0.01BLineage Cell Therapeutics, Inc.

Net margin-436.5%FY2025

P/E snapshot-10.9xone ratio, not a verdict

Prism attention16.1%share across these five

Filing track recordRevenue, USD billions

+235.3%

FY2021–FY2025 · 5 filing periods · TOTAL REVENUE · Normalized revenue metric from the in-house filings extraction · CAGR 35.3%

52-week position10% through range

$1.00$2.09

News mentions893

Community mentions18partial coverage

U.S.-scope patents99

Prism InsightsWhat sits behind the readiness signal
Observed risk 0/100higher means more observed risk

Earnings signal50/100
Management stability90/100
Market position3/100
Capital-event signal25/100
Innovation pulse0/100

Management signal

No leadership-churn flag in the model; 0 key-person events recorded in the latest 360-day window.

Market activity

Available history contains 0 M&A involvements, 1 asset-acquisition events and 0 contract events.

Innovation activity

Prism records 0 lifetime product-launch events, 0 in the latest 360 days, and 0 company announcements in that window.

Recent risk watch

No lawsuit or regulatory event is recorded in the latest 360-day window and no layoff event in the latest 180-day window. This is not legal clearance.

Prism model components and available company-event evidence; scores are research signals, not recommendations. Event totals describe available coverage and may not be exhaustive.

02 · Side-by-side

The comparisons that change the picture

Every bar preserves its own meaning. Price return, revenue scale, profitability and attention are deliberately not blended into one recommendation.

Available monthly-close return

Dated window printed on each company card; not a forecast.

Lineage Cell Therapeutics

-56.0%

Histogenics

-81.6%

Fate Therapeutics

-95.9%

Arsanis

-97.5%

Cel-Sci

-99.5%

Latest revenue

USD billions, official filing scope shown on each company card.

Arsanis

$0.04B

Lineage Cell Therapeutics

$0.01B

Fate Therapeutics

$0.01B

Histogenics

$0.00B

Cel-Sci

$0.00B

Latest profit margin

Company-card labels distinguish continuing-operations and net-income scope.

Arsanis

-225.6%

Lineage Cell Therapeutics

-436.5%

Histogenics

-1537.4%

Fate Therapeutics

-2051.1%

Cel-Sci

-10364.7%

Prism news attention

Normalized share across these five names; attention is not quality.

Histogenics

33.5%

Fate Therapeutics

21.8%

Lineage Cell Therapeutics

16.1%

Cel-Sci

15.9%

Arsanis

12.7%

03 · Prism readout

What the signals say—and what they do not

The headline share is normalized biological products, excluding disgnostic substances news attention across these five names. Partial community coverage and U.S.-scope patent records are displayed separately and are not blended into it.

Scale + attention

Histogenics leads the conversation

It holds 33.5% of measured biological products, excluding disgnostic substances news attention and also carries the basket's largest revenue base at $0.00B.

Price path

Lineage Cell Therapeutics leads the available price paths

Its monthly-close return is -56.0% for the five-year window. At the other end, Cel-Sci is -99.5% for its five-year window. Windows printed on each card must be compared carefully; price history is not a forecast.

Profitability

Arsanis has the widest latest margin

Its FY2025 net margin is -225.6%. Its revenue history in this snapshot spans only the periods printed on its card, so longer histories are not treated as equivalent.

Price vs operating signals

Lineage Cell Therapeutics shows why one ratio is not a verdict

It has the basket's lowest snapshot P/E at -10.9x while its five-year window price return is -56.0%. Valuation, price path and readiness answer different questions.

04 · Research areas

Deeper Prism readout where coverage is dense

Shown only for companies with more than 800 available Prism news records. Counts describe the available research corpus, not company quality.

Areas of research · CVM

Cel-Sci

881available Prism news records

Prism top themes

Legal, arbitration & regulatory

Price action & investor response

Capital allocation & transactions

Earnings & financial performance

Macro demand & rates

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

-79.0%52 latest 12m vs 248 prior 12m

Machine-classified coverage tone

93.8% positive-3.3 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

initial public offering 15stock price 14stock performance 14public offering 13stock surge 11relapsed hodgkin's immunotherapy 9share price 9vaccine formulation 8

Keyword tag occurrences in available Prism news records.

Coverage: 2010-01-15–2026-06-01 · trend and themes shown through 2026-06

Areas of research · FATE

Fate Therapeutics

1,208available Prism news records

Prism top themes

Leadership & governance

Price action & investor response

Legal, arbitration & regulatory

Capital allocation & transactions

Earnings & financial performance

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+20.3%166 latest 12m vs 138 prior 12m

Machine-classified coverage tone

94.2% positive+3.0 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

cell-based therapies 61stem cell banking 54cell therapy 41pluripotent stem cells 27stem cell transplantation 22somatic cell therapy 12car-t cell therapy 9gene therapy rare diseases 8

Keyword tag occurrences in available Prism news records.

Coverage: 2010-02-04–2026-06-19 · trend and themes shown through 2026-06

Areas of research · OCGN

Histogenics

1,861available Prism news records

Prism top themes

Legal, arbitration & regulatory

Price action & investor response

Earnings & financial performance

Leadership & governance

Capital allocation & transactions

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+31.1%333 latest 12m vs 254 prior 12m

Machine-classified coverage tone

89.5% positive-1.1 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

gene therapy rare diseases 152rare disease treatment 44class action securities litigation 30rare disease clinical trials 27cell-based therapies 22stock performance 22stem cell banking 17prospectus liability 14

Keyword tag occurrences in available Prism news records.

Coverage: 2011-07-28–2026-06-03 · trend and themes shown through 2026-06

Areas of research · LCTX

Lineage Cell Therapeutics

893available Prism news records

Prism top themes

Capital allocation & transactions

Earnings & financial performance

Leadership & governance

Price action & investor response

Legal, arbitration & regulatory

Mapped subcategory tag occurrences; one article may contribute more than one tag. Since 2024-01-01.

News-volume growth

+40.4%132 latest 12m vs 94 prior 12m

Machine-classified coverage tone

99.1% positive-0.9 pp vs preceding four quarters

24Q3

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

Tone of available coverage, not business performance or an investment outlook.

Frequent keywords

stem cell banking 62cell-based therapies 55cell therapy 35stem cell transplantation 29somatic cell therapy 11gene therapy rare diseases 10pluripotent stem cells 10biotherapeutics 9

Keyword tag occurrences in available Prism news records.

Coverage: 2010-07-19–2026-05-27 · trend and themes shown through 2026-05

05 · Community discussion

Common topics where conversation clears the gate

Shown only above 25 entity-matched mentions. Coverage is partial and topic counts exclude identified namesake noise.

CVM

Cel-Sci

45 mentions

Stock and valuation

Products, pricing and logistics

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 45 records remained after filtering.

FATE

Fate Therapeutics

85 mentions

Stock and valuation

Products, pricing and logistics

Workplace and hiring

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 85 records remained after filtering.

OCGN

Histogenics

29 mentions

Stock and valuation

Partial entity-matched community coverage; namesake noise is excluded before topic aggregation. 29 records remained after filtering.

06 · Company event log

Common news types and recent highlights

Event patterns and selected recent headlines come from available Prism company-event records since 2023. Obvious forecast, holdings, duplicate and retrospective noise is filtered.

CVM

Cel-Sci

through 2025-09-01

Listing / IPO 8Earnings releases 4Leadership changes 4Regulatory 4M&A 2

2025-09-01
Regulatory
It has applied for Breakthrough Medicine Designation for Multikine, an immunotherapy for head and neck cancer, with the Saudi Food & Drug Authority.
2025-08-28
Listing / IPO
CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE American: CVM), a clinical stage cancer immunotherapy company, today announced the pricing of a best-efforts public offering of 1,111,200 shares of its common stock.
2025-02-14
Leadership changes
Cel-Sci Corp. of Alexandria, Va., has hired Matthew Haines asdirector of investor relations.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

FATE

Fate Therapeutics

through 2026-05-01

Company announcements 18Lawsuits 11Earnings releases 2Leadership changes 2Listing / IPO 1

2026-05-01
Company announcements
today announced that on May 1, 2026, the Company granted restricted stock units (RSUs) representing 30,200 shares of its common stock to one newly-hired non-executive employee.
2025-10-15
Leadership changes
Fate Therapeutics, Inc. (NASDAQ: FATE) (the Company), a clinical-stage biopharmaceutical company dedicated to bringing a pipeline of induced pluripotent stem cell (iPSC)-derived off-the-shelf cellular immunotherapies to patients, today announced the appointment of Kamal Adawi, M.S., M.B.A., to the role of Chief Financial Officer (CFO) effective October 20, 2025.
2025-03-22
Earnings releases
now forecasts that the biopharmaceutical company will earn ($1.20) per share for the year

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

OCGN

Histogenics

through 2025-02-14

Listing / IPO 3

2025-02-14
Listing / IPO
Histogenics Corp. priced its IPO for expected net proceeds of approximately $57.2 million.
2025-02-14
Listing / IPO
pricing an underwritten registered direct offering of about 2.3 million shares (NASDAQ:HSGX) at $2.35 per share.
2025-02-13
Listing / IPO
Histogenics Corp. (Waltham, Mass.; HSGX)3 10/7/14 5.9S $11 12.76 Cowen and Co. (co-lead); Needham & Co. (co-lead); Canaccord Genuity (co-lead); BTIG $65

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

XFOR

Arsanis

through 2025-02-14

Listing / IPO 1

2025-02-14
Listing / IPO
Arsanis Inc., a Waltham, Mass.-based company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, saw its shares (NASDAQ:ASNS) rise 40.3 percent to close at $14.03 on Thursday, its first trading day after an IPO of 4 million shares priced at $10 per share. The IPO price was significantly below the initial $15 to $17 per share range in which the company had hoped to price. Gross proceeds were expected to be $40 million.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

LCTX

Lineage Cell Therapeutics

through 2025-10-31

Earnings releases 22Company announcements 1Leadership changes 1

2025-10-31
Earnings releases
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic, or “off the shelf”, cell therapies for serious medical conditions, today announced that it will report its third quarter 2025 financial and operating results on Thursday, November 6, 2025, following the close of the U.S. financial markets.
2024-04-01
Leadership changes
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced the appointment of veteran industry executive Charlotte Hubbert, Ph.D., as Vice President of Corporate Development.
2023-05-22
Company announcements
Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today reported that the Company is expected to be added to the broad-market Russell 3000® Index at the conclusion of the 2023 Russell indexes annual reconstitution, effective as of the U.S. market open on June 26, 2023, according to a preliminary list of additions posted to the FTSE Russell website.

Prism company-event records; exact duplicates and evident forecast, holdings and retrospective noise are excluded.

07 · Industry landscape

Biological Products, Excluding Disgnostic Substances Industry in USA

A bottom-of-page sector lens combining Prism's exact U.S. market-growth extraction with tightly matched U.S.-primary biological products, excluding disgnostic substances news. It adds context to the stock basket without turning industry signals into a recommendation.

Prism market forecast extraction

biologics market

26 sources67.0% extraction confidence

2020 extracted base$194.20B–$477.15B

2033 extracted forecast$685.30B–$1.37T

Implied source CAGR8.5%

high demand for the treatment of different disease indicationsTechnologyadvancements in biotechnology

Multi-source card returned by Prism's /special_extraction market-growth service. Extracted geography mix: Global, Asia Pacific, North America, Mexico. This is a dated market benchmark, not a forecast for the five-stock basket.

Prism news insights

U.S. Biological Products, Excluding Disgnostic Substances news pulse

24,998available Prism news records

Latest 12m volume+9.8%10786 vs 9825 records

Positive classified tone41.7%+4.6 pp vs prior four quarters

24Q4

25Q1

25Q2

25Q3

25Q4

26Q1

26Q2

26Q3

Available U.S.-primary Prism records matching biological, disgnostic, excluding, substance, biologic. Metadata counts can overlap; coverage volume and tone are not measures of industry output.

Recurring Prism themes

harm reduction strategies

4,078

substance abuse education

3,736

opioid addiction and treatment

3,643

overdose prevention techniques

3,482

controlled substance regulations

3,381

substance abuse overdose fatalities

3,287

Metadata occurrences; one record can contribute more than one theme.

Frequent industry keywords

mind-altering drug consumption 1,795opioid diversion abuse 1,702fentanyl treatment programs 1,649drug overdose 1,576cannabis policy reform discussions 1,328psychedelic mental health studies 1,328medication-assisted treatment opioids 1,265psychoactive drug intake 1,170

Counts cover the matched industry corpus, not the broader company-news totals above.

Curated signal map

Opportunity and caution, side by side

Evidence prompts—not probabilities.

Opportunity · market driver

high demand for the treatment of different disease indications

26 forecast sources

A recurring driver in the extracted market evidence provides a measurable research thread for the sector.

Prism /special_extraction market-growth card

Opportunity · demand

harm reduction strategies

4,078 matched theme records

The largest current Prism news theme shows where sector attention and reported activity are concentrating.

Prism U.S. news metadata

Opportunity · innovation

Innovation and product activity

2,049 matched news records

Technology, product and R&D metadata provide an auditable view of the sector's innovation conversation.

Unique news records matching the curated innovation rule

Caution · market restraint

Biosimilars entering the market

1,542 macro/risk records

The extracted restraint and the measured macro-news pulse belong in the downside research frame.

Prism market-growth restraint plus U.S. news metadata

Caution · news pulse

Coverage growth can reverse

+9.8% news volume

The latest 12 months contain 10,786 matched records versus 9,825 in the previous window.

Available Prism coverage through 2026-05-05

Caution · sentiment

Classified tone is not demand

41.7% positive · +4.6pp

Machine-classified news tone is useful context, but it is not revenue, output or a return forecast.

Eight-quarter Prism sentiment series

Opportunity and caution cards are curated research prompts grounded in the counts shown; they are not probabilities, recommendations or forecasts. News coverage runs 2024-01-01–2026-05-05; the latest quarter may be partial.

Explore the broader U.S. industrial landscape →

08 · Scope and sources

How to read this snapshot

Basket and ranking

Five U.S.-listed issuers classified under SEC SIC 2836 (Biological Products, Excluding Disgnostic Substances), selected as the first five names that pass all live publication gates from the Prism readiness candidate pool ranked 41–48. Every candidate has complete cached readiness evidence. This is a research cohort, not a recommendation.

Companies are ordered by the Fliar BI Prism readiness score used by the Prism Finance USA source pack. The score is a research signal, not a recommendation.

Evidence used

Official annual filingsFY revenue history and latest profitability
U.S. exchange market snapshotDated price, 52-week range, P/E, market capitalisation and monthly-close return
Fliar BI PrismReadiness, company and industry news, community context and U.S.-scope patent records
Prism market-growth extractionDated third-party Biological Products, Excluding Disgnostic Substances Industry in USA market benchmark with source-count, geography and confidence context

Important: Research and educational information only. Not investment advice, a recommendation, or a live-price service. Market figures are dated as of 02 September 2026.

09 · Final derived analysis

Conclusions, comparisons, anomalies, explanations and decisions

A final evidence-linked synthesis of the metrics already displayed above. Every named company opens its actual Companies Radar profile.

Conclusions

Cel-Sci leads the readiness ranking

Its Prism readiness score is 40/100, the highest in this five-company comparison.

Open Cel-Sci in Companies Radar

Scale and margin leadership sit with Arsanis and Arsanis

Arsanis has the largest displayed latest revenue at $0.04B; Arsanis has the widest displayed latest margin at -225.6%.

Open Arsanis in Companies Radar

Comparisons

Strongest versus weakest available price path

Lineage Cell Therapeutics is -56.0% for its five-year window; Cel-Sci is -99.5% for its five-year window.

Open Lineage Cell Therapeutics in Companies Radar Open Cel-Sci in Companies Radar

Largest versus smallest displayed revenue base

The latest displayed revenue ranges from $0.04B for Arsanis to $0.00B for Cel-Sci. Entity and filing-period labels remain visible on the company cards.

Open Arsanis in Companies Radar Open Cel-Sci in Companies Radar

Anomalies

Cel-Sci has the widest attention-readiness rank gap

It ranks #4 by measured news attention (15.9%) and #1 by Prism readiness. The gap is a review flag, not evidence that either measure is wrong.

Open Cel-Sci in Companies Radar

Arsanis shows a price-operating divergence to inspect

Its displayed filing-revenue change is +903.2% while its available monthly-close return is -97.5%. The signs differ, but the two measures cover different windows and do not establish causality.

Open Arsanis in Companies Radar

Explanations

Attention measures coverage volume, not quality

Histogenics's 33.5% share says it appears most often in the matched Prism corpus. It does not score whether that coverage is favourable or whether the company is investable.

Open Histogenics in Companies Radar

Different windows explain why signals can disagree

Revenue comes from the printed filing periods, price paths use the dated monthly-close windows, and Prism signals use their stated event windows. No causal attribution is made across them.

Research decisions

Verify the readiness leader in Companies Radar

Open Cel-Sci's company profile and inspect the underlying management, market-activity, innovation and risk evidence before relying on the 40/100 score.

Open Cel-Sci in Companies Radar

Stress-test the largest divergence before forming a view

Compare Arsanis's profile with Lineage Cell Therapeutics's profile, then reconcile the displayed filing and price windows. This is a next-research action, not a buy or sell decision.

Open Arsanis in Companies Radar Open Lineage Cell Therapeutics in Companies Radar

Method boundary: These are deterministic comparisons of the displayed snapshot fields. They flag relationships for further research, do not establish causality and are not investment recommendations.